Brief: Stoke Therapeutics Receives FDA Breakthrough Therapy Designation For Zorevunersen For The Treatment Of Dravet Syndrome
04/12/2024 12:06
Dec 4 (Reuters) - Stoke Therapeutics STOK.O :
* STOKE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY
DESIGNATION
FOR ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME
* STOKE THERAPEUTICS INC - PHASE 3 REGISTRATION STUDY UPDATE
EXPECTED BY YEAR-END
Source text: ID:nBw6M4lMYa
Further company coverage: STOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics